Menu
Login

Report Library

All Reports

Acute Lymphocytic Leukemia KOL Interview

February 09, 2016

If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only). Highlights
  • KOL specializing in stem cell transplants for hematologic malignancies
  • ALL is fairly uncommon with a high cure rate, so new therapies must target the relapsed space
  • CAR-T therapies will definitely be approved for ALL, but not settled for other B-cell malignancies
  • The neurotoxicity associated with CAR-T therapies is unpredictable and variable. The underlying pathophysiology is unknown
  • PD-1s are unlikely to be single-agent therapies for heme malignancies and unlikely to be wildly successful in aggressive heme malignancies
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Acute Lymphoblastic Leukemia (ALL)

 Additional Resources: